Evaluation of the effect of tirofiban bridging combined with aspirin in the treatment of acute cerebral infarction with beyond the thrombolytic time window
10.3760/cma.j.cn115455-20250217-00148
- VernacularTitle:替罗非班桥接阿司匹林治疗超溶栓时间窗急性脑梗死的效果评价
- Author:
Zhenling ZHU
1
;
Honglei HU
1
;
Xuguang GAO
1
;
Yajun LI
1
Author Information
1. 北京王府中西医结合医院脑病科，北京 102200
- Publication Type:Journal Article
- Keywords:
Cerebral infarction;
Tirofiban;
Aspirin;
Ultra-thrombolytic window
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(11):1015-1019
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the effect and safety of tirofiban bridging combined with aspirin for anti-platelet therapy in patients with acute cerebral infarction (ACI) beyond the thrombolytic time window.Methods:Sixty patients with ACI treated in Beijing Royal Hospital from January 2021 to September 2022 were retrospectively analyzed. Among them, 30 cases were treated with tirofiban bridging aspirin as the observation group, while 30 cases were treated with aspirin alone as the control group. The total effective rate of clinical treatment, the degree of neurological deficit, the degree of disease outcome and the incidence of adverse reactions were compared between the two groups. The degree of neurological deficit was evaluated using the National Institutes of Health stroke scale (NIHSS), and the degree of disease outcome was evaluated using the modified Rankin scale (mRS).Results:The overall effective rate in the observation group was significantly higher than that in the control group: 93.3% (28/30) vs. 66.7% (20/30), with a statistically significant difference ( χ2 = 10.97, P<0.01). Before treatment, there was no statistically significant difference in NIHSS score between the two groups ( P>0.05). However, after treatment, the NIHSS score in the observation group was significantly lower than that in the control group: (2.83 ± 1.87) scores vs. (4.93 ± 3.05) scores, indicating a significant difference ( t = -3.21, P = 0.002). No significant difference was observed in mRS score between the two groups before treatment( P>0.05). After treatment, the observation group showed significantly lower mRS score compared to the control group: 2.00 (1.00, 2.00) scores vs. 3.00 (2.00, 4.00) scores ( P = 0.006). There was no statistical difference in the incidence of adverse reactions between the observation group and control groups ( P>0.05). Conclusions:Tirofiban bridging aspirin has stronger inhibitory effect on platelet activity than simple application of aspirin for ACI patients with ultra-thrombolytic window, which can rapidly improve the degree of neurological impairment and daily living ability of patients, and the incidence of adverse reactions has not increased significantly.
